Half-life
Component-dependent (BPC: 1–4h; TB-500: hours)
Evidence Level
Preliminary
Mechanism of Action
Combines BPC-157 angiogenesis/receptor upregulation with TB-500 actin sequestration and ECM remodeling — synergistic healing pathway activation.
Published Research Ranges & Study Context
Studies have administered: Typically 5+5mg to 10+10mg weekly configurations in research literature
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Research suggests complementary mechanisms; animal studies demonstrate enhanced healing vs. individual components in some tissue models.
Preliminary
Primarily preclinical + case reports
Side Effects Observed in Research
Consistent with individual components; no notable additive adverse effects documented
Available Configurations (SKU Reference)
BB10
BB20
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on BPC+TB Blend — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.